Synopsis A recent clinical study demonstrates that Cabozantinib, a tyrosine kinase inhibitor, is highly effective in the progression of hepatocellular carcinoma. The present study aims to evaluate the effect of Cabozantinib on overall survival in patients with advanced hepatocellular carcinoma (HCC). This week’s “MED FACT” discusses a clinical trial from The New England Journal of Medicine, “ Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma” . July 5, 2018. Authors : G.K. Abou ‑Alfa, T.
Meyer, A. L. Cheng et. al. Key Takeaways: Treatment with Cabozantinib significantly improves the overall and progression-free survival in patients with previously treated advanced hepatocellular carcinoma . Objective: To evaluate the effect of Cabozantinib on overall survival in patients with advanced hepatocellular carcinoma Study Type: Randomized, double-blind,…
